trending Market Intelligence /marketintelligence/en/news-insights/trending/GecvgQehdKVa_YWhxZd6Rw2 content esgSubNav
In This List

Bristol-Myers seeks US nod for Opdivo combination as initial lung cancer therapy

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Bristol-Myers seeks US nod for Opdivo combination as initial lung cancer therapy

Bristol-Myers Squibb Co. said the U.S. Food and Drug Administration granted priority review to its application seeking approval for the combination of its cancer drugs Opdivo and Yervoy as initial treatment for non-small cell lung cancer.

The agency is expected to give its decision May 15, the New York-based pharmaceutical giant said in a Jan. 15 press release.

In its supplemental biologics license application, Bristol-Myers is seeking approval for the Opdivo-Yervoy combination to treat patients with NSCLC whose cancer has spread to another body part or is recurrent and who show no mutations of the EGFR or ALK genes.

The application is based on results from part of the Checkmate-227 phase 3 trial, which showed that the drug combination was better in extending the lifespan of the patients with previously untreated NSCLC whose tumors expressed PD-L1, a protein found on some cancer cells, as compared to chemotherapy. The Opdivo combination also improved the progression-free survival rate in these patients, meeting the second co-primary endpoint of the study.